IV immunotherapy for lingering neurologic effects after COVID-19
Part of Brain & nervous system, Infections, Lungs & breathing clinical trials.
This Phase 2 trial tests whether intravenous immunotherapy (IVIG) can improve ongoing neurologic symptoms after a mild-to-moderate COVID-19 illness. It targets people with persistent symptoms such as brain fog, fatigue, trouble thinking, dizziness when standing, and balance or other neurologic problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to understand and sign consent
- Have had COVID-19 confirmed by a positive PCR test or antibody test
- Have lingering neurologic symptoms that started after recovery (not just during the illness)
- Symptoms must be ongoing and severe enough on the trial’s symptom scale (PCFS score of at least 2)
- Be willing and able to do a brain MRI (with contrast if needed) and be available for the full study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called pembrolizumab (a type of immunotherapy) can help people with ongoing neurological symptoms after COVID-19. The goal is to see if it is safe and possibly improves symptoms like brain fog, fatigue, and dizziness.
This study looks for signs of leftover SARS-CoV-2 virus in people who have fully recovered from COVID-19, including those with ongoing neurological symptoms (like brain fog, fatigue, or nerve pain). It aims to understand why some people have long-lasting symptoms after infection.
This study uses a special PET scan to look at brain inflammation in people with neurological symptoms after COVID-19. It aims to understand how inflammation might be linked to ongoing problems like brain fog or memory issues.
This study tests whether a nasal spray form of IVIG (an immune-boosting treatment) can help people with Long COVID who also have certain immune system issues. It aims to see if the treatment is safe and effective for this group of patients.
This Phase 2 trial tests DAOIB to improve “brain fog” and thinking problems that happen after COVID-19. You may be screened if your symptoms started after a COVID infection and have lasted for months, and if your health tests are normal.
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
Hear when a new Systemic Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.